论文部分内容阅读
目的:观察戈舍瑞林联合内分泌药物治疗绝经前晚期乳腺癌的治疗效果。方法:选取2014年6月至2015年9月来我院接受治疗的绝经前晚期乳腺癌患者126例,将患者随机分为对照组和观察组,每组63例,对照组采用他莫昔芬进行治疗,观察组采用戈舍瑞林联合内分泌药物进行治疗。观察比较不同治疗方法下两组患者的治疗反应、生存时间和患者的生存情况。结果:观察组患者的生存质量和治疗反应显著优于对照组,不良反应发生率也低于对照组患者;而且观察组患者的三年总生存时间和无病情再次进展生存时间显著比对照组患者的时间长,三年总生存率也显著高于对照组。组间比较差异具有统计学意义(P<0.05)。结论:对绝经前晚期乳腺癌患者采用戈舍瑞林联合内分泌药物进行治疗后,患者的治疗效果比较显著,患者的生存质量也得到了很大的改善,总生存率比较高,具有医学价值,值得在临床治疗中大力推广。
Objective: To observe the effect of goserelin combined with endocrine drugs in the treatment of premenopausal and advanced breast cancer. Methods: A total of 126 cases of premenopausal and advanced breast cancer were treated in our hospital from June 2014 to September 2015. The patients were randomly divided into control group and observation group, with 63 cases in each group. The control group received tamoxifen For treatment, observation group using goserelin combined with endocrine drugs for treatment. The treatment response, survival time and patient survival were compared between two groups under different treatment methods. Results: The quality of life and response to treatment in the observation group were significantly better than those in the control group, and the incidence of adverse reactions was also lower than that in the control group; and the three-year overall survival time and disease-free progression-free survival time in the observation group were significantly higher than those in the control group Of the time, three-year overall survival was significantly higher than the control group. The difference between the groups was statistically significant (P <0.05). Conclusion: The treatment of goserelin combined with endocrine drugs in patients with advanced and premenopausal women with advanced breast cancer, the treatment effect is more significant, the quality of life of patients has also been greatly improved, the overall survival rate is relatively high, with medical value, It is worth to vigorously promote clinical treatment.